First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GIAll Cohorts followed to 9 months have maintained clinically meaningful improvements in tissue health as measured by EoE Histological…

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI - Life Sciences British Columbia

Open the article to view the coverage from lifesciencesbc.ca